Industrifonden leads SEK 15 million investment round in BrainZell – pioneering the future of medicine for neurological diseases

Industrifonden announced today its investment in BrainZell, a groundbreaking company dedicated to transforming thesuccess and accuracy of clinical trials targeting neurological diseases like Alzheimers. The SEK 15 million investment round was led by Industrifonden and included participation from Life Science Invest, Norrsken Accelerator, Creator Fund UK, and several prominent angel investors. BrainZell has previously received support from STING and Propel Capital.
BrainZell is at the forefront of a medical revolution, replacing and reducing traditional animal testing with advanced human cell models. By leveraging cutting-edge neuro organoids, BrainZell is shaping a more sustainable and ethical future for medicine, particularly in the field of neurological disease research.
The investment will be strategically utilized to enhance BrainZell’s proprietary AI capabilities, fortify the patents surrounding its unique portfolio of neuro organoids, and expand the company’s commercial operations into the UK and US markets.
Petra Szeszula, Co-Founder and CEO of BrainZell, commented: “We are entering an exciting new chapter at BrainZell; we’re not just advancing how drugs are tested—we’re shaping the future of medicine. This investment will be key in helping us realize our vision and make a real impact in the fight against neurological diseases.”
Mala Valroy, Investment Manager at Industrifonden, said: ”BrainZell’s novel platform is uniquely positioned to deliver the high-throughput clinically relevant insights that have been the bottleneck for discovering, designing and testing drugs to treat neurological conditions such as Alzheimers or ADHD until now. We are proud to back their bold vision and deeply impressed by their entrepreneurial spirit and scientific competence.”
About BrainZell
BrainZell is a life science deep-tech company revolutionizing medicine with its groundbreaking neuro organoid technology. We enhance the efficiency of pharmaceutical drug development and significantly reduce reliance on animal testing. Our CNS models, powered by iPS cell-derived human brain organoids, pave the way for developing safer, more effective treatments, shaping the future of brain health and medicine. Find out more at brainzell.com